Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Tredegar Corporation has appointed Cindy Yao as Vice President, Chief Financial Officer and Treasurer, effective September 21, 2026. Her compensation package includes an annual base salary of $450,000, a target bonus of 60% of base salary, and long-term incentive awards targeted at 80% of base salary consisting of restricted stock and cash.
Senior management and directors of Innventure, Inc. voluntarily forfeited 435,168 earnout shares previously issued for the achievement of 'Milestone One' under a business combination agreement. The forfeiture follows a change in status of a $15 million purchase order from DarkNX Ltd., which was the basis for the milestone, after the intended deployment site became unavailable.
Origin Bancorp, Inc. (OBK) is voluntarily withdrawing its common stock listing from the New York Stock Exchange (NYSE) to transfer to the newly established Texas Stock Exchange (TXSE). The company expects to cease trading on the NYSE at the close of business on October 12, 2026, and commence trading on the TXSE as a founding member on October 13, 2026.
5E Advanced Materials M&A Deal with Searles Valley Minerals Inc.
5E Advanced Materials has entered into a definitive asset purchase agreement to acquire the operating assets of Searles Valley Minerals through a Section 363 bankruptcy sale process. The acquisition includes critical mineral production facilities, 9,000 acres of brine resources, and integrated infrastructure in California, transforming 5E from a pre-revenue developer into an active producer of borates and boric acid. Consideration for the deal consists of $3.4 million in cash, 8.3 million shares of common stock, and a $6.2 million senior unsecured promissory note.
Cabot Corporation appointed Steven J. Delahunt as interim Chief Financial Officer, effective October 1, 2026. He replaces Erica McLaughlin, who is transitioning to the role of President and CEO, while the company continues its search for a permanent CFO. Delahunt will receive a monthly cash stipend of $35,000 in addition to his existing compensation during the interim period.
GT Biopharma entered into a securities purchase agreement for a private placement of up to 8,277.778 shares of Series M 10% Convertible Preferred Stock and associated warrants for an initial purchase price of $7.45 million. The agreement includes 'Greenshoe Rights' allowing purchasers to acquire additional preferred stock with a stated value of up to $33.33 million for an additional $30 million. The preferred stock is convertible into common stock at an initial conversion price of $6.10 per share.
Santander Holdings USA, Inc. announced it will redeem all 135,000 outstanding shares of its Series I Preferred Stock and the corresponding 5,400,000 depositary shares on October 15, 2026. The redemption will be conducted at a price of $25.00 per depositary share, totaling $135 million in cash outflows to retire the equity class.
Pulse Biosciences announced the completion of patient enrollment in its PRECISE-BTN clinical study, which evaluated the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study was expanded from 50 to 100 patients across three U.S. sites, and the first patient has already completed the final 12-month follow-up visit. Preliminary data is expected to be presented at an upcoming medical conference.
PBF Holding Company LLC priced a private offering of $500 million in 0% senior unsecured exchangeable notes due 2032. The notes are senior unsecured obligations and include an additional $50 million overallotment option for initial purchasers. The notes do not bear regular interest and are exchangeable into cash, PBF Energy common stock, or a combination thereof at an initial exchange price of approximately $96.80 per share.
Catalyst Bank entered into new three-year employment agreements with its COO Amanda Quebedeaux and CFO Jacques Bourque. The agreements establish base salaries of $162,500 and $117,500 respectively, and include provisions for 12 months of base salary as severance in the event of involuntary termination or a change in control.
Astrana Health, Inc. filed an updated corporate investor presentation for September 2026 to be used in upcoming conferences and meetings. The presentation covers the company's business strategy, expansion plans, and financial targets, including its use of artificial intelligence capabilities.
OMNIQ Corp. announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 12,633,155 B1 for its AI-based vehicle occupancy detection system used in HOV lane enforcement. The technology uses deep-learning and multiband line-scan imagery to automatically count vehicle occupants at highway speeds, addressing a total addressable U.S. market estimated at $218 million.
Summit Therapeutics announced updated overall survival (OS) results from its global Phase III HARMONi trial of ivonescimab in patients with EGFR-mutated non-small cell lung cancer. The updated June 2026 analysis showed a favorable OS hazard ratio of 0.76 in the global population, demonstrating consistent efficacy across both Western and Asian patient subgroups. No new safety signals were observed, reinforcing the potential of ivonescimab as a treatment option following progression on EGFR-targeted therapy.
Scotts Miracle-Gro $250M Debt Financing with JPMorgan Chase Bank, N.A.
Scotts Miracle-Gro redeemed $250 million of its 5.250% Senior Notes due 2026 and renewed its $750 million accounts receivable facility with JPMorgan Chase Bank through August 2027. The company also initiated its $500 million share repurchase program with $25 million in buybacks executed in August and reaffirmed its full-year fiscal 2026 guidance.
BioMarin Pharmaceutical Inc. announced its decision to discontinue the clinical development of VOXZOGO for children with Noonan syndrome. The company cited study feasibility and the current treatment landscape as reasons for the move, noting the decision was not related to safety or efficacy.
Evommune, Inc. has filed an updated corporate presentation as an exhibit to its 8-K, providing a strategic overview of its clinical-stage portfolio including EVO756, EVO301, and EVO646. The presentation outlines the company's focus on chronic inflammatory diseases and highlights its leadership team's track record of approximately 30 approved NDAs and BLAs.
Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older. The filing also clarifies that the approval includes a post-marketing requirement for a pregnancy safety study and a request for alert reports regarding bone fractures.
USA TODAY Co., Inc. has appointed Timothy Allen, the current CEO of Babbel, to its Board of Directors, effective September 15, 2026. Mr. Allen will also serve on the Audit and Transformation Committees and will receive standard pro-rated compensation for non-employee directors. The appointment increases the board size from eight to nine members.
AGNT, Inc. completed the repurchase of 8,693,290 shares of its common stock from the Gratitude 2022 Trust for approximately $32 million. The transaction was executed at a 10% discount to the 5-day volume-weighted average price to accelerate the company's capital return program and assist the trust with tax and estate administration.
Aethlon Medical amended the employment agreements for CEO/CFO James B. Frakes and CMO Steven P. LaRosa to modify severance payment terms. In the event of a change in control followed by a qualifying termination, severance and healthcare continuation payments will now be paid as a single lump sum rather than installments. The amendments do not change the total amount of compensation or the conditions required to trigger the benefits.
Otis Worldwide Corporation announced that Judith F. Marks will retire as Chair, CEO, and President effective upon the appointment of her successor, expected in the first half of 2027. The Board has initiated a formal search process for her replacement and entered into a transition agreement where Ms. Marks will serve as a senior advisor through July 31, 2027, to ensure a seamless leadership handover.
Coya Therapeutics announced it has enrolled the 100th patient in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of ALS. The company expects to complete full enrollment of 120 participants shortly and remains on track to report topline data in early Q2 2027.
Intrusion Inc. and CEO Anthony Scott have mutually agreed not to automatically renew his existing employment agreement when it expires on November 15, 2026. The parties have entered into a structured negotiation period to establish terms for a new agreement, during which Mr. Scott will continue to serve in his current roles at his existing salary and benefits.
Vera Bradley reported second quarter fiscal 2027 consolidated net revenues of $71.6 million, a 1.1% increase year-over-year, driven by 8% growth in its Direct Segment. The company achieved net income of $4.5 million compared to a net loss in the prior year, supported by improved margins and a $7.7 million tariff refund. Management reiterated its full-year sales and operating margin guidance while highlighting a 28% reduction in inventory levels.
Term
Q2 2027
Earnings call
Sep 15, 2026, 8:30 AM ET
“I’m pleased to report that our second quarter results reflect continued momentum in our transformation. This marked our second consecutive quarter of overall revenue growth, with total revenue up 1.1% versus the prior year. The underlying health of our business continued to strengthen across our direct channels, margin structure, and balance sheet.”
Ian Bickley, Chairman and Chief Executive Officer
“Based on our year-to-date performance, we continue to expect year-over-year non-GAAP operating loss improvement of at least 50%. Significant work remains, and we’re encouraged by the progress we’re seeing across all five pillars of our transformation, and we remain committed to returning the business to long-term sustainable growth, profitability, and cash flow generation.”
RB Global announced that its board of directors authorized a $500 million increase to its existing share repurchase program, raising the total aggregate value of the program from $500 million to $1 billion. The Toronto Stock Exchange approved the amendment to the company's normal course issuer bid (NCIB), which allows for the repurchase of up to 10% of the company's public float through March 2027.
LB Pharmaceuticals appointed Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026. Her compensation package includes a $515,000 base salary, a 40% target bonus, a $150,000 sign-on bonus, and an inducement grant of 200,000 stock options vesting over four years.
NextTrip announced that its travel-focused media platform, JOURNY TV, will premiere its first original series, 'I DO: In Destination', on October 4 and 5, 2026. The series is a key part of the company's 'content-to-commerce' strategy, designed to integrate travel inspiration with its booking technology. A third episode is scheduled to be filmed in The Bahamas in October 2026 with support from The Bahamas Ministry of Tourism.
Aspen Aerogels filed a formal investor presentation deck on September 15, 2026, to be used for discussions with investors and analysts. The presentation includes the company's financial outlook for the third quarter of 2026 and strategic commentary on its EV thermal barrier and Energy Industrial markets.
Sadot Group Inc. held its 2026 Annual Meeting of Stockholders on September 10, 2026, where shareholders elected five directors to serve until the 2027 annual meeting. Stockholders also approved the Sadot Group Inc. 2026 Stock Incentive Plan, which reserves 3,000,000 shares of common stock for issuance to directors, officers, and employees.
Cheetah Net Supply Chain Service Signs $788K M&A Deal with JoyPak Supply LLC
Cheetah Net Supply Chain Service Inc. entered into a definitive agreement to acquire 100% of the membership interests of JoyPak Supply LLC for $788,000 in cash. JoyPak is a Nevada-based company specializing in the sale of consumer, beauty, and personal care products. The acquisition is intended to diversify Cheetah's product mix and support its long-term growth strategy in new product categories.